文献速递神经免疫

疾病修正治疗对复发缓解型多发性硬化15年残疾的影响

Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years.
PubMed 文献 · Neurology · 2020-12-28

研究纳入14717例复发缓解型多发性硬化患者,采用边际结构模型比较治疗与未治疗期间残疾累积风险。结果显示持续免疫治疗可降低残疾进展、需要助行器的风险及复发频率,支持长期疾病修正治疗改善残疾结局。

要点

  • 持续免疫治疗降低15年残疾累积风险19%-44%。
  • 治疗期间需要助行器的风险降低67%。
  • 治疗期间复发频率降低40%-41%。

核心结论

  • 持续免疫治疗可减少复发缓解型多发性硬化患者的长期残疾累积、助行器需求及复发频率。

研究设计与样本

  • 基于MSBase数据库的观察性队列研究,纳入14717例随访≥1年的复发缓解型多发性硬化患者,其中1085例随访≥15年。
  • 采用边际结构模型比较治疗与未治疗期间12个月确认的残疾增加/减少、EDSS第6步及复发的累积风险。

主要发现

  • 治疗期间复发风险比为0.60(95%CI 0.43-0.82,p=0.0016)。
  • 治疗期间残疾加重风险比为0.56(95%CI 0.38-0.82,p=0.0026)。
  • 治疗期间进展至EDSS第6步的风险比为0.33(95%CI 0.19-0.59,p=0.00019)。
  • 随访≥15年亚组中,治疗期间复发风险比为0.59(95%CI 0.50-0.70,p=10^-9),残疾加重风险比为0.81(95%CI 0.67-0.99,p=0.043)。

临床怎么用

  • 对复发缓解型多发性硬化患者,长期持续疾病修正治疗可能改善远期残疾结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To test the hypothesis that immunotherapy prevents long-term disability in relapsing-remitting multiple sclerosis (MS), we modeled disability outcomes in 14,717 patients. METHODS: We studied patients from MSBase followed for ≥1 year, with ≥3 visits, ≥1 visit per year, and exposed to MS therapy, and a subset of patients with ≥15-year follow-up. Marginal structural models were used to compare the cumulative hazards of 12-month confirmed increase and decrease in disability, Expanded Disability Status Scale (EDSS) step 6, and the incidence of relapses between treated and untreated periods. Marginal structural models were continuously readjusted for patient age, sex, pregnancy, date, disease course, time from first symptom, prior relapse history, disability, and MRI activity. RESULTS: A total of 14,717 patients were studied. During the treated periods, patients were less likely to experience relapses (hazard ratio 0.60, 95% confidence interval [CI] 0.43-0.82, p = 0.0016), worsening of disability (0.56, 0.38-0.82, p = 0.0026), and progress to EDSS step 6 (0.33, 0.19-0.59, p = 0.00019). Among 1,085 patients with ≥15-year follow-up, the treated patients were less likely to experience relapses (0.59, 0.50-0.70, p = 10-9) and worsening of disability (0.81, 0.67-0.99, p = 0.043). CONCLUSION: Continued treatment with MS immunotherapies reduces disability accrual by 19%-44% (95% CI 1%-62%), the risk of need of a walking aid by 67% (95% CI 41%-81%), and the frequency of relapses by 40-41% (95% CI 18%-57%) over 15 years. This study provides evidence that disease-modifying therapies are effective in improving disability outcomes in relapsing-remitting MS over the long term. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that, for patients with relapsing-remitting MS, long-term exposure to immunotherapy prevents neurologic disability.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Kalincik T, Diouf I, Sharmin S, et al. Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years. Neurology. 2020. PMID: 33372028. doi:10.1212/WNL.0000000000011242

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。